Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(6-hydroxypyridin-3-yl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(6-hydroxypyridin-3-yl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 2-(6-hydroxy-3-pyridyl)-7-(trideuteriomethoxy)-5H-pyrazolo[4,3-c]quinolin-3-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in human liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(6-methoxypyridin-3-yl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 2-(6-hydroxy-3-pyridyl)-7-(trideuteriomethoxy)-5H-pyrazolo[4,3-c]quinolin-3-one metabolite formation after 60 mins by LC-MS analysis
Drug metabolism in mouse liver microsomes assessed as CYP450 mediated-O-demethylated 7-hydroxy-2-(6-methoxypyridin-3-yl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one metabolite formation after 60 mins by LC-MS analysis
Neurotoxicity in Swiss Webster mouse assessed as induction of motor impairment at 40 mg/kg administered via oral gavage measured after 10 to 60 mins by rotarod method